Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People newly diagnosed with acute lymphoblastic leukemia (a type of blood cancer affecting white blood cells)
- People newly diagnosed with a mixed type of blood cancer (called MPAL) where one blood cell type is more dominant, or where the treating doctor has a clear medical reason to use a leukemia treatment plan like the one in this trial
- People newly diagnosed with a type of blood cancer where the cancer cells have not developed clear features (called acute undifferentiated leukemia)
- People who are under 18 years old (up to 17 years and 365 days) at the time of diagnosis
- People enrolled at a participating treatment centre
- People (or their guardians) who have given written consent to take part and to have their data collected and processed
Who may not be able to join:
- People whose leukemia has a specific genetic change known as Ph+ (BCR-ABL1 or t(9;22)-positive)
- People with a mixed blood cancer where a separate group of non-lymphoblastic (a different cancer cell type) makes up 10% or more of the total cancer cells
- People who have already received chemotherapy-type (cytostatic) drugs before entering the trial
- People who have taken high-dose steroid medications (1 mg/kg/day or more) for more than two weeks in the month before diagnosis
- People who have already started treatment under a different medical protocol
- People with an existing condition that would prevent them from safely following this treatment plan — for example, a serious heart condition present from birth, or certain nerve or movement disorders (confirm with trial site)
- People whose leukemia has been diagnosed as a second cancer, where chemotherapy or radiation therapy was already given for a previous cancer
- People who are pregnant or currently breastfeeding
- Sexually active young people who are not willing to use highly effective contraception (with a Pearl Index below 1) until 12 months after completing anti-leukemia treatment
- People already taking part in another clinical trial, unless it is an add-on supportive care trial that has been approved by the trial sponsor
- People who have received a live vaccine within two weeks before starting the trial treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Martin Schrappe, MD, Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Kiel
Phone: +4943150020150
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Event-free survival; Disease-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.